131 related articles for article (PubMed ID: 17344335)
1. A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.
Gonzalez-Covarrubias V; Ghosh D; Lakhman SS; Pendyala L; Blanco JG
Drug Metab Dispos; 2007 Jun; 35(6):973-80. PubMed ID: 17344335
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER).
Gonzalez-Covarrubias V; Kalabus JL; Blanco JG
Pharm Res; 2008 Jul; 25(7):1730-4. PubMed ID: 18449627
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.
Ferguson DC; Cheng Q; Blanco JG
Drug Metab Dispos; 2015 Jul; 43(7):922-7. PubMed ID: 25918240
[TBL] [Abstract][Full Text] [Related]
4. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
[TBL] [Abstract][Full Text] [Related]
5. Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase--Carbonyl reductase 1.
Hintzpeter J; Hornung J; Ebert B; Martin HJ; Maser E
Chem Biol Interact; 2015 Jun; 234():162-8. PubMed ID: 25541467
[TBL] [Abstract][Full Text] [Related]
6. Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3).
Lakhman SS; Ghosh D; Blanco JG
Drug Metab Dispos; 2005 Feb; 33(2):254-7. PubMed ID: 15537833
[TBL] [Abstract][Full Text] [Related]
7. Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.
Quiñones-Lombraña A; Ferguson D; Hageman Blair R; Kalabus JL; Redzematovic A; Blanco JG
Pharm Res; 2014 Jul; 31(7):1644-55. PubMed ID: 24562808
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis.
El-Hawari Y; Favia AD; Pilka ES; Kisiela M; Oppermann U; Martin HJ; Maser E
Chem Biol Interact; 2009 Mar; 178(1-3):234-41. PubMed ID: 19061875
[TBL] [Abstract][Full Text] [Related]
9. Flavonoids as inhibitors of human carbonyl reductase 1.
Carlquist M; Frejd T; Gorwa-Grauslund MF
Chem Biol Interact; 2008 Jul; 174(2):98-108. PubMed ID: 18579125
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibition of human carbonyl reductase 1 (CBR1) by the prenylated chalconoid xanthohumol and its related prenylflavonoids isoxanthohumol and 8-prenylnaringenin.
Seliger JM; Martin HJ; Maser E; Hintzpeter J
Chem Biol Interact; 2019 May; 305():156-162. PubMed ID: 30849340
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional regulation of the canine carbonyl reductase 1 gene (cbr1) by the specificity protein 1 (Sp1).
Quiñones-Lombraña A; Cheng Q; Ferguson DC; Blanco JG
Gene; 2016 Oct; 592(1):209-214. PubMed ID: 27506315
[TBL] [Abstract][Full Text] [Related]
12. Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.
Varatharajan S; Abraham A; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
Eur J Clin Pharmacol; 2012 Dec; 68(12):1577-86. PubMed ID: 22562609
[TBL] [Abstract][Full Text] [Related]
13. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2010 Dec; 335(3):533-45. PubMed ID: 20837989
[TBL] [Abstract][Full Text] [Related]
14. CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver.
Quiñones-Lombraña A; Li N; Del Solar V; Atilla-Gokcumen GE; Blanco JG
Biopharm Drug Dispos; 2018 Jun; 39(6):315-318. PubMed ID: 29851133
[TBL] [Abstract][Full Text] [Related]
15. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver.
Kassner N; Huse K; Martin HJ; Gödtel-Armbrust U; Metzger A; Meineke I; Brockmöller J; Klein K; Zanger UM; Maser E; Wojnowski L
Drug Metab Dispos; 2008 Oct; 36(10):2113-20. PubMed ID: 18635746
[TBL] [Abstract][Full Text] [Related]
16. The modulation of carbonyl reductase 1 by polyphenols.
Boušová I; Skálová L; Souček P; Matoušková P
Drug Metab Rev; 2015; 47(4):520-33. PubMed ID: 26415702
[TBL] [Abstract][Full Text] [Related]
17. S-nitrosoglutathione covalently modifies cysteine residues of human carbonyl reductase 1 and affects its activity.
Hartmanová T; Tambor V; Lenčo J; Staab-Weijnitz CA; Maser E; Wsól V
Chem Biol Interact; 2013 Feb; 202(1-3):136-45. PubMed ID: 23295225
[TBL] [Abstract][Full Text] [Related]
18. Importance of the substrate-binding loop region of human monomeric carbonyl reductases in catalysis and coenzyme binding.
Miura T; Nishinaka T; Terada T
Life Sci; 2009 Aug; 85(7-8):303-8. PubMed ID: 19555696
[TBL] [Abstract][Full Text] [Related]
19. Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma.
Huang W; Ding L; Huang Q; Hu H; Liu S; Yang X; Hu X; Dang Y; Shen S; Li J; Ji X; Jiang S; Liu JO; Yu L
Hepatology; 2010 Aug; 52(2):703-14. PubMed ID: 20683966
[TBL] [Abstract][Full Text] [Related]
20. Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods.
Pirolli D; Giardina B; Mordente A; Ficarra S; De Rosa MC
Eur J Med Chem; 2012 Oct; 56():145-54. PubMed ID: 22982121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
